Kymera Therapeutics, Inc.: updates and filings

KYMRNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$115.31

November 20, 2026Market cap $9.4B

What Ploutos Investor adds for Kymera Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 73 daysAround Feb 1, 2027 · for Q4 2026

last Oct 29, 2026next Feb 1, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 26, 2026 latest annualOct 29, 2026 latest quarterly
  • Oct 29, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Oct 29, 2026Results of operations
    Form8-K
  • Oct 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Sep 8, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 5, 2026Results of operations
    Form8-K
  • Jul 27, 2026Officer or director change, Regulation FD disclosure
    Form8-K
  • Jun 26, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jun 25, 2026Regulation FD disclosure, other material events
    Form8-K
  • Jun 24, 2026Shareholder vote
    Form8-K
  • Jun 8, 2026Officer or director change
    Form8-K
  • May 15, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 6, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 30, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • Apr 30, 2026Results of operations
    Form8-K
  • Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 29, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 29, 2026Annual meeting proxy statement
    FormDEF 14A
  • Mar 27, 2026Amended articles or bylaws
    Form8-K
  • Mar 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 26, 2026Material agreement entered, material agreement ended, other material events
    Form8-K
  • Feb 26, 2026Shares registered for employees
    FormS-8

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 22, 2020.

The full analysis

What do Kymera Therapeutics's filings show?

The filings are where every one of Kymera Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.